TGTX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

32.315

Open

31.760

VWAP

31.79

Vol

1.52M

Mkt Cap

5.07B

Low

31.310

Amount

48.44M

EV/EBITDA(TTM)

41.93

Total Shares

159.69M

EV

5.17B

EV/OCF(TTM)

--

P/S(TTM)

8.32

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

Show More

Events Timeline

(ET)

2026-03-19

08:00:00

Company Board Approves Increase of Share Repurchase Program to $300 Million

2026-03-19

08:00:00

TG Therapeutics Enters $750 Million Credit Facility

2026-03-09 (ET)

2026-03-09

07:40:00

TG Therapeutics Publishes Briumvi Study Data

2026-03-02 (ET)

2026-03-02

07:31:00

Precision BioSciences Receives $7.5M Milestone Payment

2026-02-26 (ET)

2026-02-26

07:10:00

TG Therapeutics Reports Q4 Revenue of $192.6M

2026-02-26

07:10:00

2026 Target Revenue for BRIUMVI Approximately $900 Million

2026-02-26

07:10:00

Projected Cash and Investment Securities to Reach $199.5 Million by 2025

2026-02-17 (ET)

2026-02-17

07:40:00

TG Therapeutics Publishes Five-Year Data on Briumvi

News

NASDAQ.COM

03-19NASDAQ.COM

TG Therapeutics Secures $750 Million Credit Facility

seekingalpha

03-19seekingalpha

TG Therapeutics Secures $750M Credit Facility

Fool

ACT Capital Management Acquires Stake in TG Therapeutics

Newsfilter

03-12Newsfilter

Precision BioSciences Unveils PBGENE-HBV Clinical Data at AASLD

Newsfilter

03-09Newsfilter

BRIUMVI Shows Significant Efficacy in Highly Active Relapsing Multiple Sclerosis

Newsfilter

03-06Newsfilter

TG Therapeutics Announces BRIUMVI® Presentation Schedule at AAN 2026

4 Analyst Rating

Wall Street analysts forecast TGTX stock price to rise

3 Buy

0 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

15.00

Averages

43.50

High

60.00

Current: 0.000

Low

15.00

Averages

43.50

High

60.00

JPMorgan

Brian Cheng

Overweight

downgrade

$49 -> $46

AI Analysis

2026-02-02

Reason

JPMorgan

Brian Cheng

Price Target

$49 -> $46

AI Analysis

2026-02-02

downgrade

Overweight

Reason

JPMorgan analyst Brian Cheng lowered the firm's price target on TG Therapeutics to $46 from $49 and keeps an Overweight rating on the shares. The firm updated the company's model.

BofA

Alec Stranahan

Underperform

maintain

$13 -> $15

2026-01-06

Reason

BofA

Alec Stranahan

Price Target

$13 -> $15

2026-01-06

maintain

Underperform

Reason

BofA analyst Alec Stranahan raised the firm's price target on TG Therapeutics to $15 from $13 and keeps an Underperform rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TGTX

Unlock Now

Valuation Metrics

The current forward P/E ratio for TG Therapeutics Inc (TGTX.O) is 19.93, compared to its 5-year average forward P/E of 23.78. For a more detailed relative valuation and DCF analysis to assess TG Therapeutics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

23.78

Current PE

19.93

Overvalued PE

91.75

Undervalued PE

-44.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-9.15

Current EV/EBITDA

16.10

Overvalued EV/EBITDA

79.81

Undervalued EV/EBITDA

-98.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

54.53

Current PS

5.18

Overvalued PS

151.30

Undervalued PS

-42.24

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

find a stock that could rise 1000%

Intellectia · 20 candidates

Market Cap: 300.00M - 5.00BQuarter Revenue Yoy Growth: >= 40.0%Beta: HighRiskRevenue 5yr Cagr: >= 25List Exchange: XNYS, XNAS, XASETarget Price Upside Potential: MoreAbovePrice

Ticker

Name

Market Cap$

TG Therapeutics Inc

4.84B

MARA Holdings Inc

3.76B

Lucid Group Inc

3.58B

CorMedix Inc

628.74M

Real Brokerage Inc

766.72M

Procept Biorobotics Corp

1.61B

which stock will moon this year?

Intellectia · 722 candidates

Market Cap: >= 1000.00MQuarter Revenue Yoy Growth: >= 0.0%Revenue 5yr Cagr: >= 5List Exchange: XNYS, XNAS, XASEYtd Price Change Pct: >= $0.00

Ticker

Name

Market Cap$

TG Therapeutics Inc

5.02B

MARA Holdings Inc

3.89B

IREN Ltd

17.19B

Lucid Group Inc

3.72B

Nuscale Power Corp

6.25B

CleanSpark Inc

3.37B

some good stocks to buy with 50

Intellectia · 16 candidates

Market Cap: >= 2.00BPrice: <= $50.00Quarter Revenue Yoy Growth: >= 40.0%Eps Ttm: >= 2Weekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

Amcor PLC

19.57B

Annaly Capital Management Inc

16.28B

Corebridge Financial Inc

15.17B

Viper Energy Inc

14.18B

Lincoln National Corp

7.80B

Atlantic Union Bankshares Corp

5.70B

best stocks for November

Intellectia · 19 candidates

Beta: ModerateRisk, HighRiskWeekly Average Turnover: >= 20,000,000Pe Ttm: <= 15Month Price Change Pct: >= $0.00Annual Eps Yoy Growth: >= 40.0%Annual Revenue Yoy Growth: >= 40.0%

Ticker

Name

Market Cap$

Immunitybio Inc

6.82B

United States Antimony Corp

1.28B

Bakkt Holdings Inc

533.40M

Ardelyx Inc

1.94B

Gold Royalty Corp

1.10B

Two Harbors Investment Corp

1.40B

Top leverage stocks

Intellectia · 37 candidates

Market Cap: 1000.00M - 10.00BBeta: HighRiskDebt Equity: >= 2.01Weekly Average Turnover: >= 1,000,000Pe Ttm: 10 - 15

Ticker

Name

Market Cap$

Western Alliance Bancorp

9.99B

Zions Bancorporation NA

9.09B

AutoNation Inc

8.00B

PennyMac Financial Services Inc

7.91B

Jackson Financial Inc

7.77B

Carmax Inc

6.91B

biotechnology best stock to buy now

Intellectia · 7 candidates

Market Cap: >= 2.00BPe Ttm: <= 25Return On Equity: >= 10.0%Annual Revenue Yoy Growth: >= 15.0%

Ticker

Name

Market Cap$

Novo Nordisk A/S

263.42B

Genmab A/S

20.30B

Exelixis Inc

12.01B

Halozyme Therapeutics Inc

8.43B

TG Therapeutics Inc

5.01B

ACADIA Pharmaceuticals Inc

4.53B

Whales Holding TGTX

AHL Partners LLP

Trading Trends

People Also Watch

Frequently Asked Questions

What is TG Therapeutics Inc (TGTX) stock price today?

The current price of TGTX is 31.75 USD — it has decreased -0.72

What is TG Therapeutics Inc (TGTX)'s business?

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

What is the price predicton of TGTX Stock?

Wall Street analysts forecast TGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TGTX is43.50 USD with a low forecast of 15.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is TG Therapeutics Inc (TGTX)'s revenue for the last quarter?

TG Therapeutics Inc revenue for the last quarter amounts to 192.57M USD, increased 78.00

What is TG Therapeutics Inc (TGTX)'s earnings per share (EPS) for the last quarter?

TG Therapeutics Inc. EPS for the last quarter amounts to 0.14 USD, decreased -6.67

How many employees does TG Therapeutics Inc (TGTX). have?

TG Therapeutics Inc (TGTX) has 399 emplpoyees as of March 30 2026.

What is TG Therapeutics Inc (TGTX) market cap?

Today TGTX has the market capitalization of 5.07B USD.